[go: up one dir, main page]

EP0591284A1 - Carrier systems for drugs - Google Patents

Carrier systems for drugs

Info

Publication number
EP0591284A1
EP0591284A1 EP92912498A EP92912498A EP0591284A1 EP 0591284 A1 EP0591284 A1 EP 0591284A1 EP 92912498 A EP92912498 A EP 92912498A EP 92912498 A EP92912498 A EP 92912498A EP 0591284 A1 EP0591284 A1 EP 0591284A1
Authority
EP
European Patent Office
Prior art keywords
carrier system
synthetic
spherical particles
drug
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912498A
Other languages
German (de)
French (fr)
Inventor
Horst Zerbe
Jörg KREUTER
Annette Zimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of EP0591284A1 publication Critical patent/EP0591284A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin

Definitions

  • the invention relates to carrier systems for drugs, their preparation and their use.
  • the therapeutic effect of a drug inter alia is dependent on the concentration of the drug at the site of action for a desired period of time. On grounds of this dependence, factors such as distribution, dilution, excretion, absorption or biotransformation play an important role for the therapeutic effect of a drug. All of these factors must be taken into account in particular when formulating a drug.
  • U.S. Patent 4,617,186 discloses, for instance, a cationic polymer (“GAFQUAT-234") that possesses bioadhesive properties and can be used as a carrier system for drugs for the treatment of eye diseases; Moreover, this polymer is also said to be able to bind spherical particles of albumin, which also represent carrier systems for drugs.
  • the complexes of the polymer and the carrier system are said to be bioadhesive and to retard the drug release but no comparative data vis-a-vis the polymer alone are given in support of this statement.
  • cationic polymers are to be considered problematic because of their toxicological properties.
  • Solutions, ointments and specific polymers distinguish themselves in particular by their high capacity for drug incorporation. Solutions exhibit considerable disadvantages over ointments and polymers due to the fast dilution, excretion and biotransfo ⁇ nation of the drug, which entails that the drug concentration drops rapidly below the pharmaceutically active level at the site of action. Ointments, when applied to the eye, lead for example to a severe impairment of vision.
  • a disadvantage of the known spherical particles as carrier systems is above all the low drug incorporation capacity, which may also entail too low a concentration of a drug at the site of action.
  • Another disadvantage of known spherical particles is their low bioadhesiveness, which leads to a rapid excretion of- these particles.
  • the problem underlying the invention is the provision of carrier systems for drugs, which remain for a prolonged time at the site of application by an improved bioadhesiveness, exhibit a high loadability with drugs and provide a stable concentration of drugs at the site of action over the desired period of time, in order to improve the therapeutic effect of drugs.
  • the carrier system of the present invention exhibits spherical particles with a diameter of less than 1 ⁇ m, preferably less than 500 nm, most preferably 100 nm to 300 nm. In the following, such particles will also be called nanoparticles. By “particle size” the mean diameter of the particles is meant.
  • Nanoparticles as a carrier system for drugs display various advantages over the known microparticles with a diameter of at least 1 ⁇ m.
  • the nanoparticles can be better distributed in a liquid since no significant sedimentation of the particles takes place. As a rule, no surfactants need to be added in order to disperse the particles.
  • the nanoparticles can also be used as drug vehicles in inhalation aerosols.
  • the nanoparticles have a larger specific surface and thus a higher incorporation capacity. Thus they enable an enhanced effect of the drug when used as a carrier system.
  • the spherical particles of the present invention preferably contain at least one synthetic, semi-synthetic and/or natural biopolymer, most preferably a polypeptide such as albumin or gelatine.
  • Functional groups of the biopolymer such as -NH 2 , -C0 2 H, -COH or -SH permit covalent bonds with a multitude of drugs.
  • the spherical particles according to the present invention can incorporate both hydrophobic and hydrophilic drugs, wherein the loadability generally depends on the drug, e.g. 15 % by weight of pilocarpine with respect to the spherical particles, and the weight ratio of particle to drug can be up to 1:1.
  • the spherical particles are non-toxic, biodegradable by lysosomal enzymes, biocompatible, physically and chemically stable and do not possess any relevant antigenic properties.
  • the spherical particles of the invention have a controllable drug release rate and are rapidly excreted.
  • Another embodiment of the carrier system according to the present invention comprises spherical particles with a diameter of at least 1 nm and less than 1 mm, i.e. microparticles and nanoparticles, in combination with at least one bioadhesive polymer such as pectins (polygalacturonic acid) , mucopolysaccharides (hyaluronic acid, mucin) or non-toxic lectines.
  • a carrier system will also be called particle/polymer carrier system.
  • bioadhesive polymers known in the state of the art necessarily entail a synergetic effect when used as a carrier system in connection with spherical particles.
  • polysaccharides polyacrylates, alginates, polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone and lectines is preferred.
  • methyl cellulose 400 sodium carboxymethyl cellulose
  • Carbopol ® 941 hydroxypropyl methyl cellulose
  • hyaluronic acid sodium alginate MV
  • mucin and polycarbophil are preferred.
  • the bioadhesive polymers preferably have a viscosity of 4 x 10 "3 to 100 x 10 ⁇ 3 Pas, the retarded drug release being improved at a higher viscosity.
  • a higher viscosity of the polymers is advantageous.
  • the viscosity increase is restricted for practical reasons, for example in the application to the eye.
  • the weight ratio of spherical particles to bioadhesive polymer inter alia is dependent on the used polymer and can for instance be 2:1 to 1:2.
  • the bioadhesive effect of the polymers is probably due to an intermolecular interaction, such as ionic interactions, Van der aals interactions, hydrogen bonds or molecular entanglement of the polymer with surface components, such as proteins or lipids, of mucous surfaces, or to other physical phenomena, such as capillary action or viscosity.
  • a further aspect of the invention is a composition that contains at least one of the aforementioned carrier systems, a drug and optionally a further pharmaceutically acceptable carrier or diluent.
  • the weight ration of drug to carrier system is conventionally in the range of 100:1 to 1:1000, preferably
  • the preparation of the spherical particles according, to the invention can be carried out by several alternative methods. Suitable methods are the desolvation of the biopolymer used as starting material by dehydrating compounds, such as alcohols or sodium/ammonium sulfate, the thermal denaturation of the biopolymer by heating to 95°C to 195 ⁇ C, the reaction of the biopolymer with a coupling reagent and/or the reaction of the biopolymer with a compound (“hardener") having two or more functional groups, such as glutaraldehyde.
  • dehydrating compounds such as alcohols or sodium/ammonium sulfate
  • thermal denaturation of the biopolymer by heating to 95°C to 195 ⁇ C
  • the reaction of the biopolymer with a coupling reagent and/or the reaction of the biopolymer with a compound (“hardener") having two or more functional groups, such as glutaraldehyde.
  • the resultant spherical particles are suspended in a concentration of up to 10 % (w/v) in an appropriate solvent, for instance water.
  • the size as well as the diameter of the spherical particles can be optimized by varying appropriate parameters, such as temperature, concentration of the biopolymer, concentration of the hardener or selection of the dehydrating agent (e.g. absolute alcohol instead of salts) , or by further appropriate method steps, such as ultrasonication of the particles.
  • the spherical particles can also be chromatographically purified over a suitable column (gel filtration) .
  • a preferred method for the preparation of the spherical particles comprises the addition of 100 % ethanol to a solution of 0.25 to 1.5 % (w/v) of a polypeptide, preferably less than 1.25 % (w/v) of the polypeptide, in distilled water, the mixing ratio of ethanol:polypeptide solution being > 1:1 to 2:1.
  • 0.01 to 1 % (v/v) of 25 % glutaraldehyde are 1 added to said mixture.
  • a corresponding amount of a 12 % (w/v) sodium etabisulfite solution is added in order to decompose the excess glutaraldehyde.
  • the ethanol is evaporated and the obtained particle suspension column-chromatographically purified.
  • the particle-containing fraction is subsequently lyophilized while glucose is added.
  • intermolecular and ( - ) intramolecular bonds such as covalent bonds, or interactions, such as hydrophobic interaction, with particular functional groups of the biopolymer, such as -NH-,, -C0 2 H, -COH, -SH or phenyl groups, are produced.
  • functional groups of the biopolymer such as -NH-,, -C0 2 H, -COH, -SH or phenyl groups
  • the preparation of the particle/polymer carrier systems according to the invention comprises mixing at least one appropriate bioadhesive polymer with a suspension of spherical particles.
  • Said spherical particles can be produced according to the aforementioned inventive method or according to methods known in the state of the art [10-12].
  • the preparation of the composition of a drug and a carrier system according to the invention comprises the adsorption or loading of a drug into or onto the spherical particle and can be performed either simultaneously with the preparation of the carrier system by the addition of an appropriate drug solution or sequentially by the addition of a suspension of spherical particles to an appropriate drug solution. Furthermore, the preparation optionally comprises the addition of 0.1 to 2 % of a surfactant.
  • the loading process of the carrier system with a drug is probably based on a bond of the drug molecules with the carrier system, in which said molecules are complexed by intermolecular interactions, such as hydrogen bonds, with specific groups of the biopolymer, such as -NH 2 , -OH, -C00H or -SH.
  • the carrier system according to the invention can incorpor ⁇ ate a multitude of drugs, such as antiasthmatics , anal ⁇ getics, antitussiva, bronchodilators, narcotics, mucolytics, antibacterials, antifungals, antituberculosis agents, ster ⁇ oids, antitumor agents, parasympathomimetics, fibrinolytics, immunosuppressives etc.
  • the drug-loaded carrier systems according to the present invention can be administered intraarticularly, cutaneously, subcutaneously, intramuscularly, intravenously, intraarter- ially, intravaginally, rectally, orally, nasally and ocularly.
  • the drug-loaded particle/polymer carrier systems are preferably applied onto mucous surfaces of mammalians, including humans.
  • a preferred application comprises the formulation of a composition of carrier systems and drugs, which are administered for the treatment of eye diseases, such as glaucoma, inflammations, infections and allergic reactions.
  • the intended application plays an important role.
  • carrier systems that contain spherical particles with a diameter of more than 25 ⁇ m are not suitable for the application to the eye because of the pain sensation.
  • the lowest limit for the particle size is essentially not restricted by the application, however, it is difficult to produce particles with a diameter of ⁇ 10 nm.
  • particles with a diameter of ⁇ 10 nm lead to a rapid accumulation at the eye or to an exhalation in the application as an inhalation aerosol.
  • Figure 1 shows a diagram of the iotic activity of a pilocarpine composition containing albumin nanoparticles against time, with a 2 % pilocarpine solution as a reference.
  • Figure 2 shows a diagram of the miotic activity of a nanoparticle/mucin/pilocarpine composition (weight ratio 1:1.25:1) against time, with a mucin/ pilocarpine composition (weight ratio 1.25:1) as a reference.
  • Figures 3 and 4 show a diagram of- the intraocular pressure (mm Hg) of a 2 % pilocarpine solution, a microparticle/ pilocarpine composition and a nanoparticle/mucin/pilocarpine composition against time, wherein the temporal change of the pressure without the addition of a drug is defined as a baseline.
  • bovine serum albumin 500 mg bovine serum albumin are dissolved in 40 ml of distilled water and 100 % ethanol is slowly dropped in while stirring is maintained. After the addition of about 60 ml of 100% ethanol, the desolvation of the bovine serum albumin can be observed by a slight blue shimmer of the mixture.
  • 0.1 ml of 25 % glutaraldehyde is added to the mixture during stirring and subsequently agitation is continued for about 3 hours. The excess glutaraldehyde is decomposed by the addition of 1 ml of
  • the determination of the miotic activity is carried out with male albino New Zealand rabbits. Each of the experiments is performed with 5 rabbits and a dose of 50 ⁇ l of nanoparticle/pilocarpine composition. The measure ⁇ ments of the pupillary diameter are carried out under constant light conditions with a micrometer that is held at a fixed distance from the rabbit's eyes. The results are graphically depicted in Figure 1. The duration of effect of pilocarpine increases by up to 14 %, with the half-life (t 1/2) being prolonged by up to 19 %. The half-life is defined as the moment at which the miosis exhibits half of its maximum value.
  • Example 2 Nanoparticle/Mucin/Pilocarpine Composition
  • nanoparticles as described in example 1(A) are suspended in an appropriate buffer, pH 7, and 2.5 % or 4.5 % of mucin are added, solutions with viscosities of 4-7 x 10 "3 Pas or 13-17 x 10 *3 Pas, respectively, being obtained.
  • the nanoparticle composition is suspended in a 2 % pilocarpine solution as described in example 1(B), and subsequently ucin is added.
  • the determination of the miotic activity is carried out as described in example 1(C). The results are graphically depicted in Figure 2 and in Table I.
  • the effect of pilocarpine (Pilo.) is prolonged by up to 90 in (duration of effect [min]), the half-life (t 1/2) being prolonged by up to 62 %.
  • the effect of pilocarpine is directly proportional to the miosis.
  • 0.8 ml of betamethasone is subconjunctivally injected into the right eye of 13 male albino New Zealand rabbits. The injections are performed weekly over a period of 3 weeks. After three weeks, the ocular hypertension becomes stable. 50 ⁇ l of a particle/ pilocarpine composition or a particle/mucin/pilocarpine composition are subsequently instilled into the conjunctival sac and then the intraocular pressure is measured. The results are graphically depicted in Figures 3 and 4 as well as in Table II. The ti e-of- effect curve and thus the bioavailability of pilocarpine increase by up to 220 % with respect to a 2 % pilo ⁇ carpine solution.
  • the bioavailability is defined as the fraction of a drug that is determined with respect to the dose in the measuring compartment, with a direct correlation existing between the concentration and the effect of the drug.
  • the effect of pilocarpine is prolonged by up to 100 % (duration of effect [h]) .
  • Nanoparticles as described in example 1(A) are suspended in water and added to a saturated solution of hydrocortisone in ethanol (13.33 mg/ml). The mixture is ultrafiltrated through a 10 nm filter and the hydrocortisone-adsorbed nanoparticles are retained. The hydrocortisone contained in the filtrate is subsequently spectroscopically determined at 247 nm. The nanoparticles contain 6.81 % of hydrocortisone. The amount of hydrocortisone loaded onto particles with a diameter of 0.8 to 1.5 ⁇ m is 4.02 %.
  • Literature The amount of hydrocortisone loaded onto particles with a diameter of 0.8 to 1.5 ⁇ m is 4.02 %.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Systèmes d'excipients pour médicaments, leur préparation et leur utilisation. Lesdits systèmes d'excipients présentent des particules sphériques dont le diamètre est inférieur à 1 mum, éventuellement associées à un polymère biologiquement adhésif approprié. Ils présentent une adhésivité biologique améliorée et une bonne aptitude à être chargés de médicaments, et peuvent assurer une concentration stable et pharmaceutiquement active de médicaments au niveau du site d'action et pendant une période prolongée.Drug excipient systems, their preparation and their use. Said systems of excipients present spherical particles whose diameter is less than 1 mum, optionally combined with a suitable biologically adhesive polymer. They exhibit improved biological adhesiveness and good drug-loadability, and can provide a stable and pharmaceutically active concentration of drugs at the site of action and for an extended period of time.

Description

Carrier Systems for Drugs
The invention relates to carrier systems for drugs, their preparation and their use.
The therapeutic effect of a drug inter alia is dependent on the concentration of the drug at the site of action for a desired period of time. On grounds of this dependence, factors such as distribution, dilution, excretion, absorption or biotransformation play an important role for the therapeutic effect of a drug. All of these factors must be taken into account in particular when formulating a drug.
One possibility of improving the therapeutic effect of a drug is to use carrier systems such as viscous solutions, ointments, bioadhesive polymers or spherical particles [1- 9], U.S. Patent 4,617,186 discloses, for instance, a cationic polymer ("GAFQUAT-234") that possesses bioadhesive properties and can be used as a carrier system for drugs for the treatment of eye diseases; Moreover, this polymer is also said to be able to bind spherical particles of albumin, which also represent carrier systems for drugs. The complexes of the polymer and the carrier system are said to be bioadhesive and to retard the drug release but no comparative data vis-a-vis the polymer alone are given in support of this statement. Furthermore, in particular cationic polymers are to be considered problematic because of their toxicological properties. Solutions, ointments and specific polymers distinguish themselves in particular by their high capacity for drug incorporation. Solutions exhibit considerable disadvantages over ointments and polymers due to the fast dilution, excretion and biotransfoπnation of the drug, which entails that the drug concentration drops rapidly below the pharmaceutically active level at the site of action. Ointments, when applied to the eye, lead for example to a severe impairment of vision. A disadvantage of the known spherical particles as carrier systems is above all the low drug incorporation capacity, which may also entail too low a concentration of a drug at the site of action. Another disadvantage of known spherical particles is their low bioadhesiveness, which leads to a rapid excretion of- these particles.
The problem underlying the invention is the provision of carrier systems for drugs, which remain for a prolonged time at the site of application by an improved bioadhesiveness, exhibit a high loadability with drugs and provide a stable concentration of drugs at the site of action over the desired period of time, in order to improve the therapeutic effect of drugs.
This problem is solved by the features of the claims.
In a first embodiment, the carrier system of the present invention exhibits spherical particles with a diameter of less than 1 μm, preferably less than 500 nm, most preferably 100 nm to 300 nm. In the following, such particles will also be called nanoparticles. By "particle size" the mean diameter of the particles is meant.
Nanoparticles as a carrier system for drugs display various advantages over the known microparticles with a diameter of at least 1 μm. The nanoparticles can be better distributed in a liquid since no significant sedimentation of the particles takes place. As a rule, no surfactants need to be added in order to disperse the particles. The nanoparticles can also be used as drug vehicles in inhalation aerosols. The nanoparticles have a larger specific surface and thus a higher incorporation capacity. Thus they enable an enhanced effect of the drug when used as a carrier system.
The spherical particles of the present invention preferably contain at least one synthetic, semi-synthetic and/or natural biopolymer, most preferably a polypeptide such as albumin or gelatine. Functional groups of the biopolymer such as -NH2, -C02H, -COH or -SH permit covalent bonds with a multitude of drugs.
The spherical particles according to the present invention can incorporate both hydrophobic and hydrophilic drugs, wherein the loadability generally depends on the drug, e.g. 15 % by weight of pilocarpine with respect to the spherical particles, and the weight ratio of particle to drug can be up to 1:1.
The spherical particles are non-toxic, biodegradable by lysosomal enzymes, biocompatible, physically and chemically stable and do not possess any relevant antigenic properties.
Furthermore, the spherical particles of the invention have a controllable drug release rate and are rapidly excreted.
Another embodiment of the carrier system according to the present invention comprises spherical particles with a diameter of at least 1 nm and less than 1 mm, i.e. microparticles and nanoparticles, in combination with at least one bioadhesive polymer such as pectins (polygalacturonic acid) , mucopolysaccharides (hyaluronic acid, mucin) or non-toxic lectines. In the following, such a carrier system will also be called particle/polymer carrier system. Not all bioadhesive polymers known in the state of the art necessarily entail a synergetic effect when used as a carrier system in connection with spherical particles. The use of polysaccharides, polyacrylates, alginates, polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone and lectines is preferred. Most preferred is the use of methyl cellulose 400, sodium carboxymethyl cellulose, Carbopol® 941, hydroxypropyl methyl cellulose, hyaluronic acid, sodium alginate MV, mucin and polycarbophil.
The bioadhesive polymers preferably have a viscosity of 4 x 10"3 to 100 x 10~3 Pas, the retarded drug release being improved at a higher viscosity. Generally, a higher viscosity of the polymers is advantageous. However, the viscosity increase is restricted for practical reasons, for example in the application to the eye. The weight ratio of spherical particles to bioadhesive polymer inter alia is dependent on the used polymer and can for instance be 2:1 to 1:2.
The advantages of particle/polymer carrier systems for drugs over pure particle carrier systems are on the one hand an increased incorporation capacity due to an increased adsorption of the drug molecules and on the other hand a lower required dose of the drug due to a prolonged effect of the drug and thus less discomfort for the patient.
The bioadhesive effect of the polymers is probably due to an intermolecular interaction, such as ionic interactions, Van der aals interactions, hydrogen bonds or molecular entanglement of the polymer with surface components, such as proteins or lipids, of mucous surfaces, or to other physical phenomena, such as capillary action or viscosity.
A further aspect of the invention is a composition that contains at least one of the aforementioned carrier systems, a drug and optionally a further pharmaceutically acceptable carrier or diluent. The weight ration of drug to carrier system is conventionally in the range of 100:1 to 1:1000, preferably
10:1 to 1:10 and most preferably 2:1 to 1:2 or 2:1 to 1:1.
The preparation of the spherical particles according, to the invention can be carried out by several alternative methods. Suitable methods are the desolvation of the biopolymer used as starting material by dehydrating compounds, such as alcohols or sodium/ammonium sulfate, the thermal denaturation of the biopolymer by heating to 95°C to 195βC, the reaction of the biopolymer with a coupling reagent and/or the reaction of the biopolymer with a compound ("hardener") having two or more functional groups, such as glutaraldehyde.
The resultant spherical particles are suspended in a concentration of up to 10 % (w/v) in an appropriate solvent, for instance water.
The size as well as the diameter of the spherical particles can be optimized by varying appropriate parameters, such as temperature, concentration of the biopolymer, concentration of the hardener or selection of the dehydrating agent (e.g. absolute alcohol instead of salts) , or by further appropriate method steps, such as ultrasonication of the particles. Furthermore, the spherical particles can also be chromatographically purified over a suitable column (gel filtration) .
A preferred method for the preparation of the spherical particles comprises the addition of 100 % ethanol to a solution of 0.25 to 1.5 % (w/v) of a polypeptide, preferably less than 1.25 % (w/v) of the polypeptide, in distilled water, the mixing ratio of ethanol:polypeptide solution being > 1:1 to 2:1. After the onset of the polypeptide desolvation, 0.01 to 1 % (v/v) of 25 % glutaraldehyde are 1 added to said mixture. After about 1 hour, a corresponding amount of a 12 % (w/v) sodium etabisulfite solution is added in order to decompose the excess glutaraldehyde. After about 3 hours, the ethanol is evaporated and the obtained particle suspension column-chromatographically purified. The particle-containing fraction is subsequently lyophilized while glucose is added.
When preparing the spherical particles, intermolecular and (-) intramolecular bonds, such as covalent bonds, or interactions, such as hydrophobic interaction, with particular functional groups of the biopolymer, such as -NH-,, -C02H, -COH, -SH or phenyl groups, are produced.'
5 The preparation of the particle/polymer carrier systems according to the invention comprises mixing at least one appropriate bioadhesive polymer with a suspension of spherical particles. Said spherical particles can be produced according to the aforementioned inventive method or according to methods known in the state of the art [10-12].
The preparation of the composition of a drug and a carrier system according to the invention comprises the adsorption or loading of a drug into or onto the spherical particle and can be performed either simultaneously with the preparation of the carrier system by the addition of an appropriate drug solution or sequentially by the addition of a suspension of spherical particles to an appropriate drug solution. Furthermore, the preparation optionally comprises the addition of 0.1 to 2 % of a surfactant.
The loading process of the carrier system with a drug is probably based on a bond of the drug molecules with the carrier system, in which said molecules are complexed by intermolecular interactions, such as hydrogen bonds, with specific groups of the biopolymer, such as -NH2, -OH, -C00H or -SH. The carrier system according to the invention can incorpor¬ ate a multitude of drugs, such as antiasthmatics , anal¬ getics, antitussiva, bronchodilators, narcotics, mucolytics, antibacterials, antifungals, antituberculosis agents, ster¬ oids, antitumor agents, parasympathomimetics, fibrinolytics, immunosuppressives etc.
The drug-loaded carrier systems according to the present invention can be administered intraarticularly, cutaneously, subcutaneously, intramuscularly, intravenously, intraarter- ially, intravaginally, rectally, orally, nasally and ocularly. The drug-loaded particle/polymer carrier systems are preferably applied onto mucous surfaces of mammalians, including humans.
A preferred application comprises the formulation of a composition of carrier systems and drugs, which are administered for the treatment of eye diseases, such as glaucoma, inflammations, infections and allergic reactions.
When selecting the particle size, the intended application plays an important role. For example, carrier systems that contain spherical particles with a diameter of more than 25 μm are not suitable for the application to the eye because of the pain sensation. The lowest limit for the particle size is essentially not restricted by the application, however, it is difficult to produce particles with a diameter of < 10 nm. Furthermore, particles with a diameter of < 10 nm lead to a rapid accumulation at the eye or to an exhalation in the application as an inhalation aerosol.
In the following the invention will be explained in more detail by means of the drawings. Figure 1 shows a diagram of the iotic activity of a pilocarpine composition containing albumin nanoparticles against time, with a 2 % pilocarpine solution as a reference.
Figure 2 shows a diagram of the miotic activity of a nanoparticle/mucin/pilocarpine composition (weight ratio 1:1.25:1) against time, with a mucin/ pilocarpine composition (weight ratio 1.25:1) as a reference.
Figures 3 and 4 show a diagram of- the intraocular pressure (mm Hg) of a 2 % pilocarpine solution, a microparticle/ pilocarpine composition and a nanoparticle/mucin/pilocarpine composition against time, wherein the temporal change of the pressure without the addition of a drug is defined as a baseline.
The following examples illustrate the invention.
Example 1: Albumin Nanoparticle/Pilocarpine Composition
(A) The Preparation of the Albumin Nanoparticles
500 mg bovine serum albumin are dissolved in 40 ml of distilled water and 100 % ethanol is slowly dropped in while stirring is maintained. After the addition of about 60 ml of 100% ethanol, the desolvation of the bovine serum albumin can be observed by a slight blue shimmer of the mixture. 0.1 ml of 25 % glutaraldehyde is added to the mixture during stirring and subsequently agitation is continued for about 3 hours. The excess glutaraldehyde is decomposed by the addition of 1 ml of
12 % sodium etabisulfite solution. After further 3 hours of agitation, the ethanol is evaporated under vacuum. The remainder is chromatographically purified over a Sephacryl S-1000 column (Pharmacia) . The obtained particle suspension is lyophilized by the addition of glucose for about 16 hours. The particle diameter in this method is 100 to 200 nm (measured with particle measuring device BI-90, Brook Haven Instruments).
(B) Pilocarpine-Loading
20 g/ml of the nanoparticles are added to a 2 % pilocarpine nitrate solution (containing 1.2 % of pluronic F 68, 1 % of sodium sulfate, phosphate- buffered, pH 7) and the mixture is equilibrated to reach an equilibrium while stirring. The mixture is then filtrated by ultrafiltration and the amount of the free pilocarpine is spectroscopically determined. The amount of incorporated pilocarpine is 11.8 mg/100 mg carrier. The amount of incorporated pilocarpine in the case of particles with a diameter of 1-2 μm is only 5.8 mg/100 mg carrier.
(C) Determination of the Miotic Activity
The determination of the miotic activity is carried out with male albino New Zealand rabbits. Each of the experiments is performed with 5 rabbits and a dose of 50 μl of nanoparticle/pilocarpine composition. The measure¬ ments of the pupillary diameter are carried out under constant light conditions with a micrometer that is held at a fixed distance from the rabbit's eyes. The results are graphically depicted in Figure 1. The duration of effect of pilocarpine increases by up to 14 %, with the half-life (t 1/2) being prolonged by up to 19 %. The half-life is defined as the moment at which the miosis exhibits half of its maximum value. Example 2: Nanoparticle/Mucin/Pilocarpine Composition
(A) The Preparation of the Bovine Serum Albumin/Mucin
Composition
The nanoparticles as described in example 1(A) are suspended in an appropriate buffer, pH 7, and 2.5 % or 4.5 % of mucin are added, solutions with viscosities of 4-7 x 10"3 Pas or 13-17 x 10*3 Pas, respectively, being obtained.
(B) Pilocarpine-Loading
The nanoparticle composition is suspended in a 2 % pilocarpine solution as described in example 1(B), and subsequently ucin is added.
(C) Determination of the Miotic Activity
The determination of the miotic activity is carried out as described in example 1(C). The results are graphically depicted in Figure 2 and in Table I. The effect of pilocarpine (Pilo.) is prolonged by up to 90 in (duration of effect [min]), the half-life (t 1/2) being prolonged by up to 62 %. The effect of pilocarpine is directly proportional to the miosis.
TABLE I
Carrier System Measuring I max ' Duration AUCC ' tl/2 timea-1 [min] [mm] [min] [min]
Mucin 2.5% Micro- 30 2.66 300 386.40 130 particle 2% Pilo. 2%
Mucin 2.5% Pilo. 2% 30 2.40 210 230.74 97
Reference
Mucin 2.5% Nano- 15 4.26 300 631.95 155 particle 2% Pilo. 2%
Mucin 2.5% Pilo. 2% 30 3.68 210 394.53. 122
Reference
Mucin 4.5% Micro- 30 3.08 300 425.25 135 particle 4% Pilo. 2%
Mucin 4.5% Nano- 30 4.15 300 629.74 157 particle 4% Pilo. 2%
a) moment of maximum pupillary contraction b) maximum pupillary contraction c) "area under the curve" ( integral of the time-of- effect curve)
(D) Determination of the Intraocular Pressure (Betamethasone
Model)
0.8 ml of betamethasone is subconjunctivally injected into the right eye of 13 male albino New Zealand rabbits. The injections are performed weekly over a period of 3 weeks. After three weeks, the ocular hypertension becomes stable. 50 μl of a particle/ pilocarpine composition or a particle/mucin/pilocarpine composition are subsequently instilled into the conjunctival sac and then the intraocular pressure is measured. The results are graphically depicted in Figures 3 and 4 as well as in Table II. The ti e-of- effect curve and thus the bioavailability of pilocarpine increase by up to 220 % with respect to a 2 % pilo¬ carpine solution. The bioavailability is defined as the fraction of a drug that is determined with respect to the dose in the measuring compartment, with a direct correlation existing between the concentration and the effect of the drug. The effect of pilocarpine is prolonged by up to 100 % (duration of effect [h]) .
Mucin 4.5% Micro- 7.0 31.53 319.12 particle 4% Pilo. 2%
Example 3: Loadinσ of Hydrocortisone onto Nanoparticles
Nanoparticles as described in example 1(A) are suspended in water and added to a saturated solution of hydrocortisone in ethanol (13.33 mg/ml). The mixture is ultrafiltrated through a 10 nm filter and the hydrocortisone-adsorbed nanoparticles are retained. The hydrocortisone contained in the filtrate is subsequently spectroscopically determined at 247 nm. The nanoparticles contain 6.81 % of hydrocortisone. The amount of hydrocortisone loaded onto particles with a diameter of 0.8 to 1.5 μm is 4.02 %. Literature:
[I] U.S. Patent 4,617,186; [2] Ribinson, J.R. et al. (1984), 231-236 in: Recent advances in glaucoma, eds. Ticho et al. , Elsevier
Science Publishers B.V.; [3] Ch'ng, H.S. et al. (1985), J.Pharm. Science 74 (4),
399-405; [4] Park, K. et al. (1984), Int. J. Pharmaceutics 19, 107-
127; [5] Langer, M.A. et al. (1985), J.Pharm. Science 74 (4),
406-411; [6] Wood, R.W. et al. (1985) , Int. J. Pharmaceutics 23,
175-183; [7] U.S. Patent 4,671,954; [8] U.S. Patent 4,582,719;
[9] Lehr et al. (1989), Proceed. Intern. Symp. Control.
Rel. Bioact. Mater., 16, 418-419; [10] U.S. Patent 4,107,288;
[II] Knop, G et al. (1974), Nuklearmedizinisches Symposium in Reinhardsbrunn DDR, 315-319;
[12] Widder, K. et al. (1979), J. Pharm. Sci. 68, 79- 82.

Claims

C L A I M S
1. A carrier system for drugs, said carrier system comprising spherical particles with a diameter of less than 1 μm.
2. The carrier system according to claim 1, wherein the spherical particles have a diameter of less than 500 nm.
3. The carrier system according to claim 1, wherein the spherical particles have a diameter of 100 to 300 nm.
4. A carrier system for drugs, said carrier system comprising spherical particles with a diameter of at least 1 nm and less than 1 mm, and at least one bioadhesive polymer.
5. The carrier system according to claim 4, wherein the bioadhesive polymer has a viscosity of 4 x 10~3 to 100 x 10"3 Pas.
6. The carrier system according to claim 4 or 5, wherein the bioadhesive polymer is neutral or anionic.
7. The carrier system according to any of claims 4 to 6, wherein the bioadhesive polymer is selected from the group consisting of polysaccharide, polyacrylate, alginate, polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone and lectine.
8. The carrier system according to any of claims 4 to 7, wherein the bioadhesive polymer is selected from the group consisting of methyl cellulose 400, sodium carboxymethyl cellulose, Carbopol® 941, hydroxypropyl methyl cellulose, hyaluronic acid, sodium alginate MV, mucin and polycarbophil.
9. The carrier system according to any of claims 1 to 8, wherein the spherical particles consist of at least one synthetic, semi-synthetic or natural biopolymer.
10. The carrier system according to claim 9, wherein the biopolymer is the protein albumin.
11. A composition consisting of a carrier system according to any of claims 1 to 10 and a drug.
12. The composition according to claim 11, wherein the weight ratio of drug to carrier system is in the range of 100:1 to 1:100.
13. A method for preparing a carrier system according to any of claims 1 to 3, said method comprising at least one of the following method steps in the preparation of the spherical particles:
(A) desolvation of a synthetic, semi-synthetic or natural biopolymer,
(B) thermal denaturation of a synthetic, semi-synthetic or natural biopolymer,
(C) reaction of a synthetic, semi-synthetic or natural biopolymer with a coupling reagent, and/or
(D) reaction of a synthetic, semi-synthetic or natural biopolymer with a compound that contains two or more functional groups.
14. The method according to claim 13, wherein the compound in step (D) is glutaraldehyde.
15. A method for preparing a carrier system according to any of claims 4 to 10, said method comprising at least one of the method steps (A) to (D) according to claim 13, and the further step of mixing the formed spherical particles with at least one bioadhesive polymer.
16. A method for preparing a composition according to claim 11 or 12, said method comprising the step of adding an appropriate drug solution
(A) during the preparation of the carrier system according to the method of any of claims 13 to 15, and/or
(B) after the preparation of the carrier system according to the method of any of claims 13 to 15.
17. A method of treatment comprising administering to a patient in need of such a treatment a composition according to claim 11 or 12.
EP92912498A 1991-06-24 1992-06-24 Carrier systems for drugs Withdrawn EP0591284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19914120760 DE4120760A1 (en) 1991-06-24 1991-06-24 CARRIER SYSTEMS FOR MEDICINAL PRODUCTS
DE4120760 1991-06-24
PCT/EP1992/001425 WO1993000076A1 (en) 1991-06-24 1992-06-24 Carrier systems for drugs

Publications (1)

Publication Number Publication Date
EP0591284A1 true EP0591284A1 (en) 1994-04-13

Family

ID=6434592

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912498A Withdrawn EP0591284A1 (en) 1991-06-24 1992-06-24 Carrier systems for drugs

Country Status (4)

Country Link
EP (1) EP0591284A1 (en)
JP (1) JPH06508369A (en)
DE (1) DE4120760A1 (en)
WO (1) WO1993000076A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208339D0 (en) * 1992-04-15 1992-06-03 Unilever Plc Treatment composition
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH10511957A (en) * 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン Surface-modified nanoparticles and methods for their production and use
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
DE19737481A1 (en) * 1997-08-28 1999-03-04 Hoechst Ag Microparticles containing spherical linear polysaccharides
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
DE19839212C2 (en) 1998-08-28 2002-05-23 Celanese Ventures Gmbh Process for the production of spherical nanoparticles which consist wholly or partly of at least one water-insoluble linear polysaccharide
DE19839214C1 (en) * 1998-08-28 2000-05-25 Aventis Res & Tech Gmbh & Co Process for the production of spherical microparticles with a smooth surface which consist wholly or partly of at least one water-insoluble linear polysaccharide, and microparticles obtainable by this process and their use
DE19860371A1 (en) * 1998-12-28 2000-06-29 Aventis Res & Tech Gmbh & Co Cosmetic or medical preparation for topical use
DE19961277A1 (en) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh Use of nanoscale polymers
CN1211076C (en) 2000-02-17 2005-07-20 3M创新有限公司 Delivery devices and methods using preformed biodegradable polymer compositions
WO2001074400A1 (en) 2000-04-03 2001-10-11 Santen Pharmaceutical Co., Ltd. Transporters and drug delivery system by using the same
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
CN1318093C (en) * 2001-09-28 2007-05-30 参天制药株式会社 Injections for eye tissue containing drug bound to polyethylene glycol
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
DE10329087B4 (en) 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigen-containing microspheres for allergy therapy
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
BRPI0700832B8 (en) * 2007-03-16 2021-05-25 Biolab Sanus Farmaceutica Ltda topical anesthetic composition comprising suspension of polymeric nanocapsules of lidocaine and prilocaine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9300076A1 *

Also Published As

Publication number Publication date
DE4120760A1 (en) 1993-03-04
JPH06508369A (en) 1994-09-22
WO1993000076A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
EP0591284A1 (en) Carrier systems for drugs
Sultana et al. Review of ocular drug delivery
CA2127805C (en) Composition for nasal administration
EP0766555B1 (en) Nanoparticles stabilized and filterable in sterile conditions
US4847091A (en) Pharmaceutical composition including sodium cromoglycate
CA1282405C (en) Method for making uniformly sized particles from water-insoluble organic compounds
US5461081A (en) Topical ophthalmic pharmaceutical vehicles
US5599534A (en) Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use
US5252318A (en) Reversible gelation compositions and methods of use
JPH09509166A (en) Sustained release delivery system for ophthalmic liquids
JPH07504663A (en) Compositions for controlled delivery of drug compounds
JPH06504051A (en) Formulation of stable suspensions for controlled delivery of drug compounds
JP2003519083A (en) A novel formulation of fexofenadine
JP3043795B2 (en) Protein gel ophthalmic vehicle
JPH10501814A (en) In situ gel-forming delivery vehicles for biological agents and methods of use
CA2147362C (en) Topical ophthalmic pharmaceutical vehicles
JPH04210910A (en) Ophthalmic liquid composition based on lipid microparticles containing at least one active ingredient
EP0490305A2 (en) Microspheres for ophthalmic use
AU661944B2 (en) An aqueous suspension
JPH08510731A (en) In situ produced gel for therapeutic use
WO1993018748A1 (en) Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
EP0424042B1 (en) Non-solid ophthalmic composition and process for preparing the said composition
US10780070B2 (en) Alpha-aminoadipate for treatment of vision loss and restoring sight
EP1366758A1 (en) Novel ophthalmic compositions
Shastri et al. Novel alternative to ocular drug delivery system: Hydrogel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19940511

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980210